Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Relief Therapeutics announced that Jack Weinstein, the Chief Financial Officer, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relief Therapeutics announced that Jack Weinstein, the Chief Financial Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference scheduled for September 13, 2022, at 1:30 PM ET. The event runs from September 12-14, 2022, where management will conduct one-on-one meetings with registered institutional investors. A live webcast of the presentation will be available on Relief’s website and archived for 90 days. Relief focuses on developing treatments for rare diseases and has ongoing collaborations and product pipelines addressing significant unmet medical needs.
Details
News Market Reaction – RLFTF
The recorded move for RLFTF in the trading session of this news was -3.80%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GENEVA, SWITZERLAND / ACCESSWIRE / September 7, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specialty, rare and ultra-rare diseases with high unmet need, today announced that Jack Weinstein, Chief Financial Officer and Treasurer, will present a company overview during the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 12-14, 2022.
Date: Tuesday, September 13, 2022
Time: 1:30 pm ET
Management will host one-on-one meetings during the event. Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company.
A live webcast of Relief's presentation will be available on the Company's website at: https://www.relieftherapeutics.com/news-and-events and will be archived for a period of 90 days after the conference.
ABOUT RELIEF
Relief is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of rare and ultra-rare diseases including metabolic disorders, pulmonary diseases and connective tissue disorders. Relief's diversified pipeline consists of assets that have the potential to effectively address significant unmet medical needs, including PKU GOLIKE®, engineered with the proprietary Physiomimic technology, which is the first prolonged-release amino acid product commercialized for the dietary management of phenylketonuria ("PKU"). Relief has a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including Urea Cycle Disorders ("UCDs") and Maple Syrup Urine Disease (MSUD). Relief also continues to develop aviptadil for several rare pulmonary indications. Relief is in clinical development for APR-TD011, a differentiated acid oxidizing solution of hypochlorous acid intended for the treatment of epidermolysis bullosa ("EB"), a group of rare, genetic, life-threatening connective tissue disorders; APR-TD011 has been granted Orphan Drug Designation by the FDA. In addition, Relief is commercializing several legacy products via licensing and distribution partners.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com. Follow Relief on LinkedIn.
CONTACT:
RELIEF THERAPEUTICS Holding AG
Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com
FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
SOURCE: Relief Therapeutics Holdings AG
View source version on accesswire.com:
https://www.accesswire.com/714937/Relief-Therapeutics-to-Participate-in-the-HC-Wainwright-24th-Annual-Global-Investment-Conference
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.